26 results on '"Bogaerts, Jan"'
Search Results
2. Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.
- Author
-
Nakajima, Erica C., Simpson, Amber, Bogaerts, Jan, de Vries, Elisabeth G.E., Do, Richard, Garalda, Elena, Goldmacher, Greg, Kinahan, Paul E., Lambin, Philippe, LeStage, Barbara, Li, Qin, Lin, Frank, Litière, Saskia, Perez-Lopez, Raquel, Petrick, Nicholas, Schwartz, Lawrence, Seymour, Lesley, Shankar, Lalitha, and Laurie, Scott A.
- Subjects
RADIOMICS ,ANTINEOPLASTIC agents ,INDIVIDUALIZED medicine ,DRUG development ,CLINICAL medicine ,ONCOLOGY nursing ,CLINICAL trials monitoring - Abstract
Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials. This paper by the RECIST Working Group outlines a path to realize the potential of radiomics as a precision biomarker. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial.
- Author
-
Jacob, Laurent, Witteveen, Anke, Beumer, Inès, Delahaye, Leonie, Wehkamp, Diederik, van den Akker, Jeroen, Snel, Mireille, Chan, Bob, Floore, Arno, Bakx, Niels, Brink, Guido, Poncet, Coralie, Bogaerts, Jan, Delorenzi, Mauro, Piccart, Martine, Rutgers, Emiel, Cardoso, Fatima, Speed, Terence, van 't Veer, Laura, and Glas, Annuska
- Subjects
GENE expression ,DNA microarrays ,RANDOMIZED controlled trials ,DEVELOPMENTAL stability (Genetics) ,GENETIC regulation - Abstract
Gene expression data obtained in large studies hold great promises for discovering disease signatures or subtypes through data analysis. It is also prone to technical variation, whose removal is essential to avoid spurious discoveries. Because this variation is not always known and can be confounded with biological signals, its removal is a challenging task. Here we provide a step-wise procedure and comprehensive analysis of the MINDACT microarray dataset. The MINDACT trial enrolled 6693 breast cancer patients and prospectively validated the gene expression signature MammaPrint for outcome prediction. The study also yielded a full-transcriptome microarray for each tumor. We show for the first time in such a large dataset how technical variation can be removed while retaining expected biological signals. Because of its unprecedented size, we hope the resulting adjusted dataset will be an invaluable tool to discover or test gene expression signatures and to advance our understanding of breast cancer. Laurent Jacob et al. develop a workflow and analytical pipeline to remove technical variation from the MINDACT microarray dataset. Their method preserved biological signals and the normalized datasets can be repurposed for the discovery of other biomarkers and signatures for breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Late translational research: putting forward a new model for developing new anti‐cancer treatments that addresses the needs of patients and society.
- Author
-
Lacombe, Denis, Bogaerts, Jan, Tombal, Bertrand, Maignen, François, Osipienko, Leeza, Sullivan, Richard, and Golfinopoulos, Vassilis
- Published
- 2019
- Full Text
- View/download PDF
5. Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques.
- Author
-
Vandenberghe, Sjouke, Duchateau, Luc, Slaets, Leen, Bogaerts, Jan, and Vansteelandt, Stijn
- Subjects
PATHOLOGY ,CANCER chemotherapy ,BREAST cancer patients ,MEDIATION therapy ,ANTHRACYCLINES - Abstract
The meta-analytic approach is the gold standard for validation of surrogate markers, but has the drawback of requiring data from several trials. We refine modern mediation analysis techniques for time-to-event endpoints and apply them to investigate whether pathological complete response can be used as a surrogate marker for disease-free survival in the EORTC 10994/BIG 1-00 randomised phase 3 trial in which locally advanced breast cancer patients were randomised to either taxane or anthracycline based neoadjuvant chemotherapy. In the mediation analysis, the treatment effect is decomposed into an indirect effect via pathological complete response and the remaining direct effect. It shows that only 4.2% of the treatment effect on disease-free survival after five years is mediated by the treatment effect on pathological complete response. There is thus no evidence from our analysis that pathological complete response is a valuable surrogate marker to evaluate the effect of taxane versus anthracycline based chemotherapies on progression free survival of locally advanced breast cancer patients. The proposed analysis strategy is broadly applicable to mediation analyses of time-to-event endpoints, is easy to apply and outperforms existing strategies in terms of precision as well as robustness against model misspecification. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. A population-based approach to compare patient-reported outcomes of long-term Hodgkin's lymphoma survivors according to trial participation: a joint study from the Patient-Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship registry and European Organisation for Research and Treatment of Cancer
- Author
-
Thong, Melissa S. Y., Kicinski, Michal, Coens, Corneel, Giusti, Francesco, van de Poll-Franse, Lonneke, Bogaerts, Jan, and Lifang Liu
- Published
- 2017
- Full Text
- View/download PDF
7. Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.
- Author
-
Liu, Lifang, Giusti, Francesco, Schaapveld, Michael, Aleman, Berthe, Lugtenburg, Pieternella, Meijnders, Paul, Hutchings, Martin, Lemmens, Valery, Bogaerts, Jan, and Visser, Otto
- Subjects
HODGKIN'S disease treatment ,TREATMENT effectiveness ,CANCER treatment ,LIFE expectancy ,QUALITY of life ,CLINICAL trials - Abstract
The survival of patients diagnosed with Hodgkin lymphoma ( HL) has improved from 70% to 90% in clinical trials. However, population-based data has shown lower survival. In this study, clinical trial data were linked with cancer registry to identify trial and non-trial participants and differences in overall survival and associated factors were assessed. In 1986-2004, 27% of HL patients aged 15-70 years participated in clinical trials. Compared to non-trial participants, trial participants were younger (median age, 31 vs. 34 years), had staging registered more accurately and had an 8% higher 20-year survival rate (73% vs. 65%). After adjusting for baseline differences, no differences in survival (hazard ratio = 0·96, 95% confidence interval 0·82-1·12), or in subgroup analysis according to stage, remained. Over time, increased administration of chemotherapy in combination with radiotherapy, together with the decreased use of radiotherapy alone was observed among the trial population. This trend was later followed in non-trial participants, coinciding with a similar 'take-up' in survival. The observed superior survival among patients with HL treated in clinical trials can be largely explained by the differences in baseline characteristics, particularly younger age. High trial participation rate and centralized expertise facilitates the implementation of trial findings to real-world practice. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer.
- Author
-
Viale, Giuseppe, Slaets, Leen, Snoo, Femke, Bogaerts, Jan, Russo, Leila, Veer, Laura, Rutgers, Emiel, Piccart-Gebhart, Martine, Stork-Sloots, Lisette, Dell'Orto, Patrizia, Glas, Annuska, and Cardoso, Fatima
- Abstract
Accurate identification of breast cancer patients most likely to benefit from adjuvant systemic therapies is crucial. Better understanding of differences between methods can lead to an improved ER, PgR, and HER-2 assessment. The purpose of this preplanned translational research is to investigate the correlation of central IHC/FISH assessments with microarray mRNA readouts of ER, PgR, and HER-2 status in the MINDACT trial and to determine if any discordance could be attributed to intratumoral heterogeneity or the DCIS and normal tissue components in the specimens. MINDACT is an international, prospective, randomized, phase III trial investigating the clinical utility of MammaPrint in selecting patients with early breast cancer for adjuvant chemotherapy ( n = 6694 patients). Gene-expression data were obtained by TargetPrint; IHC and/or FISH were assessed centrally ( n = 5788; 86 %). Macroscopic and microscopic evaluation of centrally submitted FFPE blocks identified 1427 cases for which the very same sample was submitted for gene-expression analysis. TargetPrint ER had a positive agreement of 98 %, and a negative agreement of 95 % with central pathology. Corresponding figures for PgR were 85 and 94 % and for HER-2 72 and 99 %. Agreement of mRNA versus central protein was not different when the same or a different portion of the tumor tissue was analyzed or when DCIS and/or normal tissue was included in the sample subjected to mRNA assays. This is the first large analysis to assess the discordance rate between protein and mRNA analysis of breast cancer markers, and to look into intratumoral heterogeneity, DCIS, or normal tissue components as a potential cause of discordance. The observed difference between mRNA and protein assessment for PgR and HER-2 needs further research; the present analysis does not support intratumoral heterogeneity or the DCIS and normal tissue components being likely causes of the discordance. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.
- Author
-
Ming-Wen An, Xinxin Dong, Meyers, Jeffrey, Yu Han, Grothey, Axel, Bogaerts, Jan, Sargent, Daniel J., Mandrekar, Sumithra J., An, Ming-Wen, Dong, Xinxin, Han, Yu, and Response Evaluation Criteria in Solid Tumors Steering Committee
- Subjects
TUMOR growth ,CANCER prognosis ,NON-small-cell lung carcinoma ,BREAST cancer ,COLON cancer ,ANTHROPOMETRY ,BREAST tumors ,COLON tumors ,LUNG cancer ,LUNG tumors ,PROBABILITY theory ,PROGNOSIS ,RECTUM tumors ,RESEARCH funding ,TUMORS ,PREDICTIVE tests ,PROPORTIONAL hazards models ,STATISTICAL models ,ODDS ratio - Abstract
Background: We sought to develop and validate clinically relevant, early assessment continuous tumor measurement-based metrics for predicting overall survival (OS) using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 data warehouse.Methods: Data from 13 trials representing 2096 patients with breast cancer, non-small cell lung cancer (NSCLC), or colorectal cancer were used in a complete case analysis. Tumor measurements from weeks 0-6-12 assessments were used to evaluate the ability of slope (absolute change in tumor size from 0-6 and 6-12 weeks) and percent change (relative change in tumor size from 0-6 and 6-12 weeks) metrics to predict OS using Cox models, adjusted for average baseline tumor size. Metrics were evaluated by discrimination (via concordance or c-index), calibration (goodness-of-fit type statistics), association (hazard ratios), and likelihood (Bayesian Information Criteria), with primary focus on the c-index. All statistical tests were two-sided.Results: Comparison of c-indices suggests slight improvement in predictive ability for the continuous tumor measurement-based metrics vs categorical RECIST response metrics, with slope metrics performing better than percent change metrics for breast cancer and NSCLC. However, these differences were not statistically significant. The goodness-of-fit statistics for the RECIST metrics were as good as or better than those for the continuous metrics. In general, all the metrics performed poorly in breast cancer, compared with NSCLC and colorectal cancer.Conclusion: Absolute and relative change in tumor measurements do not demonstrate convincingly improved overall survival predictive ability over the RECIST model. Continued work is necessary to address issues of missing tumor measurements and model selection in identifying improved tumor measurement-based metrics. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
10. Cavitation: a blessing in disguise? New method to establish vulnerability curves and assess hydraulic capacitance of woody tissues.
- Author
-
Vergeynst, Lidewei L., Dierick, Manuel, Bogaerts, Jan A. N., Cnudde, Veerle, and Steppe, Kathy
- Subjects
CAVITATION ,WOODY plants ,TISSUES ,HYDRODYNAMICS ,PLANTS - Abstract
The hydraulic performance of woody species during drought is currently of high interest in the context of climate change. It is known that woody species have the capacity to mitigate water shortage by using internally stored water. Elastic shrinkage of living cells and also water release during cavitation contribute to the so-called 'hydraulic capacitance' (C) of the plant, which adds water to the transpiration stream and buffers fluctuations in water potential. Although sap-conducting conduits may ultimately serve as a water pool, cavitation will hamper the conduction of sap. Both hydraulic conductivity and C are thus inextricably linked and the interaction between both should be studied to better understand hydraulic functioning of woody species during drought. However, measurements of C are scarce and no distinction is usually made between C from elastic storage and C supplied by cavitation. In this paper, we propose a new method to assess both the decrease in hydraulic conductivity and the change in C during bench dehydration of a whole-branch segment using continuous measurements of acoustic emissions, radial diameter shrinkage and gravimetrical water loss. With this method we could establish proper vulnerability curves for grapevine (Vitis vinifera L. 'Johanniter') and quantify C during dehydration. Our results showed that loss in hydraulic conductivity during the cavitation phase was accompanied by 22-92% gain in hydraulic capacitance; therefore, a certain degree of cavitation may be tolerated in grapevine during periods of drought stress. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. NIR-enhanced image sensor using multiple epitaxial layers.
- Author
-
Dierickx, Bart and Bogaerts, Jan
- Published
- 2004
- Full Text
- View/download PDF
12. The dream and reality of histology agnostic cancer clinical trials.
- Author
-
Lacombe, Denis, Burock, Susen, Bogaerts, Jan, Schoeffski, Patrick, Golfinopoulos, Vassilis, and Stupp, Roger
- Published
- 2014
- Full Text
- View/download PDF
13. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98.
- Author
-
Senkus, Elżbieta, Gomez, Henry, Dirix, Luc, Jerusalem, Guy, Murray, Elizabeth, Van Tienhoven, Geertjan, Westenberg, A. Helen, Bottomley, Andrew, Rapion, Jérôme, Bogaerts, Jan, Di Leo, Angelo, and Nešković‐Konstantinović, Zora
- Subjects
ANTINEOPLASTIC agents ,INFERTILITY ,BREAST cancer patients ,CANCER chemotherapy ,CANCER treatment - Abstract
Objective Infertility due to anticancer treatments is a major source of distress for young patients with cancer. A survey was performed among breast cancer patients younger than 35 years, to evaluate the acceptance of chemotherapy in the context of infertility risk. Methods After obtaining written informed consent, we asked 400 premenopausal, early stage breast cancer patients aged ≤35 years to complete a short, previously pilot-tested questionnaire. Three hundred and eighty-nine patients were evaluable. The association between the explanatory variables and the outcome variables was assessed using logistic regression. Results Two hundred and twenty-eight (59%) participants wanted to have (more) children in the future, whereas 158 (41%) did not. Fifty-seven (36%) of the latter did not want additional children because of fear of cancer recurrence. Thirty-two women (8%) stated they would not accept chemotherapy should it reduce their fertility. This was dependent upon already having children, the wish to have (further) children, geographical area, disease stage, and already planned chemotherapy. One hundred and seventy-one women who would agree to chemotherapy (48%) would accept a risk of infertility of 76-100%. This acceptance was dependent on already having children and the wish to have (more) children. Of the 355 participants (91%) accepting chemotherapy, 48 would accept it only for ≥20% gain in cure. Conclusion For the majority of young patients with breast cancer, cure remains their first priority; for this, they are willing to accept a considerable decrease in future fertility, and only less than 10% will forego chances of cure to preserve fertility. Copyright © 2013 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Characterization of Backside-Illuminated CMOS APS Prototypes for the Extreme Ultraviolet Imager On-Board Solar Orbiter.
- Author
-
BenMoussa, Ali, Giordanengo, Boris, Gissot, Samuel, Meynants, Guy, Xinyang Wang, Wolfs, Bram, Bogaerts, Jan, Schühle, Udo, Berger, Guy, Gottwald, Alexander, Laubis, Christian, Kroth, Udo, and Scholze, Frank
- Subjects
ACTIVE pixel sensors ,CMOS image sensors ,PIXELS ,SPACE vehicle electronics ,PROTOTYPES ,ASTRONAUTICS - Abstract
For the Extreme Ultraviolet Imager (EUI) of the Solar Orbiter mission, to be launched in 2017, CMOS active pixel sensor (APS) prototypes have been developed with several test pixel designs. A set of measurements was carried out to evaluate their performance characteristics in visible and in extreme ultraviolet wavelengths. We present the results of measurement campaigns that lead to the selection of a preferred pixel design in regard to the scientific performance requirements of the EUI flight model detectors, i.e., back-thinned CMOS APS devices of 2048 × 2048 and 3072 × 3072 pixel formats with a 10-μm pixel pitch. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
15. Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS Trial.
- Author
-
Straver, Marieke, Meijnen, Philip, Tienhoven, Geertjan, Velde, Cornelis, Mansel, Robert, Bogaerts, Jan, Duez, Nicole, Cataliotti, Luigi, Klinkenbijl, Jean, Westenberg, Helen, Mijle, Huub, Snoj, Marko, Hurkmans, Coen, and Rutgers, Emiel
- Abstract
The randomized EORTC 10981-22023 AMAROS trial investigates whether breast cancer patients with a tumor-positive sentinel node biopsy (SNB) are best treated with an axillary lymph node dissection (ALND) or axillary radiotherapy (ART). The aim of the current substudy was to evaluate the identification rate and the nodal involvement. The first 2,000 patients participating in the AMAROS trial were evaluated. Associations between the identification rate and technical, patient-, and tumor-related factors were evaluated. The outcome of the SNB procedure and potential further nodal involvement was assessed. In 65 patients, the sentinel node could not be identified. As a result, the sentinel node identification rate was 97% (1,888 of 1,953). Variables affecting the success rate were age, pathological tumor size, histology, year of accrual, and method of detection. The SNB results of 65% of the patients ( n = 1,220) were negative and the patients underwent no further axillary treatment. The SNB results were positive in 34% of the patients ( n = 647), including macrometastases ( n = 409, 63%), micrometastases ( n = 161, 25%), and isolated tumor cells ( n = 77, 12%). Further nodal involvement in patients with macrometastases, micrometastases, and isolated tumor cells undergoing an ALND was 41, 18, and 18%, respectively. With a 97% detection rate in this prospective international multicenter study, the SNB procedure is highly effective, especially when the combined method is used. Further nodal involvement in patients with micrometastases and isolated tumor cells in the sentinel node was similar—both were 18%. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. Time-Delay-Integration Architectures in CMOS Image Sensors.
- Author
-
Lepage, Gérald, Bogaerts, Jan, and Meynants, Guy
- Subjects
TIME delay systems ,IMAGE converters ,CCD cameras ,COMPLEMENTARY metal oxide semiconductors ,OPTICAL transfer function ,PIXELS ,ELECTRONIC noise ,SIGNAL-to-noise ratio - Abstract
Difficulty and challenges of implementing time-delay-integration (TDI) functionality in a CMOS technology are studied: synchronization of the samples forming a TDI pixel, adder matrix outside the array, and addition noise. Existing and new TDI sensor architecture concepts with snapshot shutter, rolling shutter, or orthogonal readout are presented. An optimization method is then introduced to inject modulation transfer function and quantum efficiency specification in the architecture definition. Moderate spatial and temporal oversamplings are combined to achieve near charge-coupled device (CCD) class performances, resulting in an acceptable design complexity. Finally, CCD and CMOS dynamic range and signal-to-noise ratio are conceptually compared. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
17. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study.
- Author
-
Mook, Stella, Schmidt, Marjanka, Viale, Giuseppe, Pruneri, Giancarlo, Eekhout, Inge, Floore, Arno, Glas, Annuska, Bogaerts, Jan, Cardoso, Fatima, Piccart-Gebhart, Martine, Rutgers, Emiel, and Veer, Laura
- Abstract
Purpose The 70-gene prognosis-signature has shown to be a valid prognostic tool in node-negative breast cancer. Although axillary lymph node status is considered to be one of the most important prognostic factors, still 25–30% of node-positive breast cancer patients will remain free of distant metastases, even without adjuvant systemic therapy. We therefore investigated whether the 70-gene prognosis-signature can accurately identify patients with 1–3 positive lymph nodes who have an excellent disease outcome. Methods Frozen tumour samples from 241 patients with operable T1-3 breast cancer, and 1–3 positive axillary lymph nodes, with a median follow-up of 7.8 years, were selected from 2 institutes. Using a customized microarray, tumour samples were analysed for the 70-gene tumour expression signature. In addition, we reanalysed part of a previously described cohort ( n = 106) with extended follow-up. Results The 10-year distant metastasis-free (DMFS) and breast cancer specific survival (BCSS) probabilities were 91% (SE 4%) and 96% (SE 2%), respectively for the good prognosis-signature group (99 patients), and 76% (SE 4%) and 76% (SE 4%), respectively for the poor prognosis-signature group (142 patients). The 70-gene signature was significantly superior to the traditional prognostic factors in predicting BCSS with a multivariate hazard ratio (HR) of 7.17 (95% CI 1.81 to 28.43; P = 0.005). Conclusions The 70-gene prognosis-signature outperforms traditional prognostic factors in predicting disease outcome in patients with 1–3 positive nodes. Moreover, the signature can accurately identify patients with an excellent disease outcome in node-positive breast cancer, who may be safely spared adjuvant chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
18. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.
- Author
-
van Nes, Johanna, Putter, Hein, Julien, Jean-Pierre, Tubiana-Hulin, Michelle, van de Vijver, Marc, Bogaerts, Jan, de Vos, Monika, and van de Velde, Cornelis
- Abstract
Introduction The Preoperative Chemotherapy in Primary Operable Breast Cancer (POCOB) study was designed to compare preoperative with postoperative chemotherapy in patients with early breast cancer concerning breast conserving therapy (BCT) procedures, disease free survival (DFS) and overall survival (OS). Methods Patients ( n = 698) with early breast cancer were enrolled between 1991 and 1999 and randomized between preoperative versus postoperative chemotherapy (four cycles of fluorouracil, epirubicin, and cyclophosphamide). Endpoints were BCT procedures, DFS, OS, and tumor response to preoperative chemotherapy. In addition, tumor tissue was collected for translational research and the following markers were examined: ER, PgR, HER2, p21, p53, and bcl-2 expression. Results With a median follow-up of 10 years, there was no statistically significant difference between the two treatment arms for OS (HR = 1.09; 95%CI 0.83–1.42; P = 0.54), DFS (HR = 1.12; 95%CI 0.90–1.39; P = 0.30), or locoregional recurrences (LRR, HR = 1.16; 95%CI 0.77–1.74). Preoperative chemotherapy was associated with an increase in BCT rates. BCT in part feasible due to tumor downsizing after preoperative chemotherapy was not correlated with higher LRR or worse OS compared to BCT which was feasible without downsizing of the tumor. Using available tumor material, only tumor stage, nodal stage, and grade were independent prognostic factors for overall survival. Conclusions Preoperative chemotherapy does not result in a difference in OS or DFS compared to postoperative chemotherapy in patients with early breast cancer. Moreover, it increases BCT rates with no significant increase of LRR. This implies that preoperative chemotherapy is a safe procedure for patients with early breast cancer, even after a follow-up period of 10 years. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
19. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.
- Author
-
Farmer, Pierre, Bonnefoi, Hervé, Anderle, Pascale, Cameron, David, Wirapati, Pratyakasha, Becette, Véronique, André, Sylvie, Piccart, Martine, Campone, Mario, Brain, Etienne, MacGrogan, Gaëtan, Petit, Thierry, Jassem, Jacek, Bibeau, Frédéric, Blot, Emmanuel, Bogaerts, Jan, Aguet, Michel, Bergh, Jonas, Iggo, Richard, and Delorenzi, Mauro
- Subjects
TUMORS ,DRUG therapy ,GENE expression ,BIOPSY ,BREAST cancer - Abstract
To better understand the relationship between tumor-host interactions and the efficacy of chemotherapy, we have developed an analytical approach to quantify several biological processes observed in gene expression data sets. We tested the approach on tumor biopsies from individuals with estrogen receptor–negative breast cancer treated with chemotherapy. We report that increased stromal gene expression predicts resistance to preoperative chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in subjects in the EORTC 10994/BIG 00-01 trial. The predictive value of the stromal signature was successfully validated in two independent cohorts of subjects who received chemotherapy but not in an untreated control group, indicating that the signature is predictive rather than prognostic. The genes in the signature are expressed in reactive stroma, according to reanalysis of data from microdissected breast tumor samples. These findings identify a previously undescribed resistance mechanism to FEC treatment and suggest that antistromal agents may offer new ways to overcome resistance to chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
20. Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer.
- Author
-
Buyse, Marc, Loi, Sherene, van't Veer, Laura, Viale, Giuseppe, Delorenzi, Mauro, Glas, Annuska M., Saghatchian d'Assignies, Mahasti, Bergh, Jonas, Lidereau, Rosette, Ellis, Paul, Harris, Adrian, Bogaerts, Jan, Therasse, Patrick, Floore, Arno, Amakrane, Mohamed, Piette, Fanny, Rutgers, Emiel, Sotiriou, Christos, Cardoso, Fatima, and Piccart, Martine J.
- Subjects
BREAST cancer ,CANCER in women ,CANCER risk factors ,RISK assessment ,CANCER invasiveness - Abstract
Background: A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients. Methods: Patients (n = 307, with 137 events after a median follow-up of 13.6 years) from five European centers were divided into high- and low-risk groups based on the gene signature classification and on clinical risk classifications. Patients were assigned to the gene signature low-risk group if their 5-year distant metastasis-free survival probability as estimated by the gene signature was greater than 90%. Patients were assigned to the clinicopathologic low-risk group if their 10-year survival probability, as estimated by Adjuvant! software, was greater than 88% (for estrogen receptor FERI-positive patients) or 92% (for ER- negative patients). Hazard ratios (HRs) were estimated to compare time to distant metastases, disease-free survival, and overall survival in high- versus low-risk groups. Results: The 70-gene signature outperformed the clinicopathologic risk assessment in predicting all endpoints. For time to distant metastases, the gene signature yielded HR = 2.32 (95% confidence interval [CII = 1.35 to 4.00) without adjustment for clinical risk and hazard ratios ranging from 2.13 to 2.15 after adjustment for various estimates of clinical risk; clinicopathologic risk using Adjuvant! software yielded an unadjusted HR = 1.68(95% CI = 0.92 to 3.07). For overall survival, the gene signature yielded an unadjusted HR = 2.79 (95% CI = 1.60 to 4.87) and adjusted hazard ratios ranging from 2.63 to 2.89; clinicopathologic risk yielded an unadjusted HR = 1.67 (95% CI = 0.93 to 2.98). For patients in the gene signature high-risk group, 10-year overall survival was 0.69 for patients in both the low- and high-clinical risk groups; for patients in the gene signature low-risk group, the 10-year survival rates were 0.88 and 0.89, respectively. Conclusions: The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
21. Total Dose and Displacement Damage Effects in a Radiation-hardened CMOS APS.
- Author
-
Bogaerts, Jan, Dierickx, Bart, Meynants, Guy, and Uwaerts, Dirk
- Subjects
COMPLEMENTARY metal oxide semiconductors ,RADIATION tolerance ,PROTONS - Abstract
A 512 × 512 CMOS active pixel sensor (APS) was designed and fabricated in a standard 0.5-µm technology. The radiation tolerance of the sensor has been evaluated with Co-60 and proton irradiation with proton energies ranging from 11.7 to 59 MeV. The most pronounced radiation effect is the increase of the dark current. However, the total ionizing dose-induced dark current increase is orders of magnitude smaller than in standard devices. It behaves logarithmically with dose and anneals at room temperature. The dark current increase due to proton displacement damage is explained in terms of the nonionizing energy loss of the protons. The fixed pattern noise does not increase with total ionizing dose. Responsivity changes are observed after Co-60 and proton irradiation, but a definitive cause has not yet been established. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
22. Reduction of Electrical Crosstalk in Hybrid Backside Illuminated CMOS Imagers using Deep Trench Isolation.
- Author
-
Minoglou, Kyriaki, de Munck, Koen, Tezcan, Deniz Sabuncuoglu, Borgers, Tom, Ruythooren, Wouter, Bogaerts, Jan, Veltroni, Iacopo Ficai, Zayer, Igor, Meynart, Roland, Bezy, Jean-Loup, van Hoof, Chris, and de Moor, Piet
- Published
- 2008
- Full Text
- View/download PDF
23. RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
- Author
-
Cherny, Nathan I, Dafni, Urani, Bogaerts, Jan, Latino, Nicola J, Douillard, Jean-Yves, Pentheroudakis, George, Tabernero, Josep, Zielinski, Christoph, Piccart, Martine J, Vries, Elisabeth G E de, and de Vries, Elisabeth G E
- Subjects
ONCOLOGY ,MEDICAL care - Published
- 2018
- Full Text
- View/download PDF
24. 6.3 105?65mm2 391Mpixel CMOS image sensor with >78dB dynamic range for airborne mapping applications.
- Author
-
Bogaerts, Jan, Lafaille, Raf, Borremans, Marc, Guo, Jia, Ceulemans, Bart, Meynants, Guy, Sarhangnejad, Navid, Arsinte, Gavril, Statescu, Victor, and van der Groen, Sonja
- Published
- 2016
- Full Text
- View/download PDF
25. Erratum: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.
- Author
-
Farmer, Pierre, Bonnefoi, Hervé, Anderle, Pascale, Cameron, David, Wirapati, Pratyaksha, Becette, Véronique, André, Sylvie, Piccart, Martine, Campone, Mario, Brain, Etienne, MacGrogan, Gaëtan, Petit, Thierry, Jassem, Jacek, Bibeau, Frédéric, Blot, Emmanuel, Bogaerts, Jan, Aguet, Michel, Bergh, Jonas, Iggo, Richard, and Delorenzi, Mauro
- Subjects
BREAST cancer - Abstract
A correction to the article "A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer" that was published in a prior issue is presented.
- Published
- 2009
- Full Text
- View/download PDF
26. CMOS sensors write their name in the stars.
- Author
-
Bogaerts, Jan
- Subjects
COMPLEMENTARY metal oxide semiconductors ,CHARGE coupled devices ,SPACE exploration ,INTEGRATED circuits ,SIGNAL processing ,DETECTORS - Abstract
The article reports that CMOS active pixel sensors are ideal replacements for charge-coupled device (CCD) in applications for space exploration. Optical sensors are the core components in scientific imaging applications and attitude and orbit control systems. Currently applications are mainly served by CCD technology. These developments are driven by the idea that those applications can cash-in on CMOS APS's inherent advantages such as low power operation on a single power supply, on-chip integration of analogue circuitry and digital functionality, and lower direct processing cost.
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.